0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Anti-hypertension -Epidemiology Forecast to 2028
Published Date: April 2019
|
Report Code: DELV-Epid-151
Home | Market Reports | Health | Health Conditions
Anti hypertension Epidemiology Forecast to 2028

Anti-hypertension -Epidemiology Forecast to 2028

Code: DELV-Epid-151
Report
April 2019
50 Pages
Delveinsight
Region: Global,
Description
Table of Content
Tables & Figures

DelveInsight's "Anti-hypertension - Epidemiology Forecast, 2028” report provides a comprehensive analysis of the Anti-hypertension epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered
• United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2016-2028

Anti-hypertension Epidemiology
The epidemiology section covers the historical, current as well as forecasted epidemiology for Anti-hypertension in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders’ views are also taken into account to provide a deep understanding of the Anti-hypertension outlook. It also includes the explanation of changing trends of epidemiology outlining the Anti-hypertension scenario.

Anti-hypertension Epidemiology Segmentation
The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Anti-hypertension thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope
• The report covers detailed overview of Anti-hypertension explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
• The Anti-hypertension Report assesses the disease risk and burden and highlights the unmet needs
• It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths
• 10 Year Forecast
• 7MM Coverage
• Total Cases in Anti-hypertension

Key assessments
• Patient Segmentation in Anti-hypertension
• Anti-hypertension Risk & Burden
• Factors driving growth in a specific Anti-hypertension patient population

1. Report Introduction
2. Anti-hypertension Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Anti-hypertension in 2016
2.2. Patient Share Distribution of Anti-hypertension in 2028
3. Disease Background and Overview: Anti-hypertension
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Anti-hypertension in 7MM
4.3. Total Prevalent/ Incident Patient Population of Anti-hypertension in 7MM – By Countries
5. Epidemiology of Anti-hypertension by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Anti-hypertension
5.1.3. Sub-Type Specific cases of the Anti-hypertension *
5.1.4. Sex- Specific Cases of the Anti-hypertension*
5.1.5. Diagnosed Cases of the Anti-hypertension
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Anti-hypertension
5.4.3. Sub-Type Specific cases of the Anti-hypertension*
5.4.4. Sex- Specific Cases of the Anti-hypertension*
5.4.5. Diagnosed Cases of the Anti-hypertension
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Anti-hypertension
5.5.3. Sub-Type Specific cases of the Anti-hypertension*
5.5.4. Sex- Specific Cases of the Anti-hypertension*
5.5.5. Diagnosed Cases of the Anti-hypertension
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Anti-hypertension
5.6.3. Sub-Type Specific cases of the Anti-hypertension*
5.6.4. Sex- Specific Cases of the Anti-hypertension*
5.6.5. Diagnosed Cases of the Anti-hypertension
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Anti-hypertension
5.7.3. Sub-Type Specific cases of the Anti-hypertension*
5.7.4. Sex- Specific Cases of the Anti-hypertension*
5.7.5. Diagnosed Cases of the Anti-hypertension
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Anti-hypertension
5.8.3. Sub-Type Specific cases of the Anti-hypertension*
5.8.4. Sex- Specific Cases of the Anti-hypertension*
5.8.5. Diagnosed Cases of the Anti-hypertension
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Anti-hypertension
5.9.3. Sub-Type Specific cases of the Anti-hypertension*
5.9.4. Sex- Specific Cases of the Anti-hypertension*
5.9.5. Diagnosed Cases of the Anti-hypertension
6. Unmet Needs of the Anti-hypertension
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables :

Table 1: Total Prevalent/Incident Cases of the Anti-hypertension in 7MM
Table 2: Total Prevalent/Incident Cases of the Anti-hypertension in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Anti-hypertension in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Anti-hypertension in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Anti-hypertension in United States (2016-2028)*
Table 6: Diagnosed Cases of the Anti-hypertension in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Anti-hypertension in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Anti-hypertension in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Anti-hypertension in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Anti-hypertension in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Anti-hypertension in France (2016-2028)
Table 12: Sub-Type Specific cases of the Anti-hypertension in France (2016-2028) *
Table 13: Sex- Specific Cases of the Anti-hypertension in France (2016-2028) *
Table 14: Diagnosed Cases of the Anti-hypertension in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Anti-hypertension in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Anti-hypertension in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Anti-hypertension in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Anti-hypertension in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Anti-hypertension in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Anti-hypertension in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Anti-hypertension in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Anti-hypertension in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Anti-hypertension in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Anti-hypertension in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Anti-hypertension in UK (2016-2028) *
Table 26: Diagnosed Cases of the Anti-hypertension in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Anti-hypertension in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Anti-hypertension in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Anti-hypertension in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Anti-hypertension in Japan (2016-2028)

List of Figures :

Figure 1: Total Prevalent/Incident Cases of the Anti-hypertension in 7MM
Figure 2: Total Prevalent/Incident Cases of the Anti-hypertension in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Anti-hypertension in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Anti-hypertension in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Anti-hypertension in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Anti-hypertension in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Anti-hypertension in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Anti-hypertension in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Anti-hypertension in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Anti-hypertension in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Anti-hypertension in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Anti-hypertension in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Anti-hypertension in France (2016-2028) *
Figure 14: Diagnosed Cases of the Anti-hypertension in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Anti-hypertension in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Anti-hypertension in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Anti-hypertension in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Anti-hypertension in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Anti-hypertension in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Anti-hypertension in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Anti-hypertension in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Anti-hypertension in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Anti-hypertension in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Anti-hypertension in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Anti-hypertension in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Anti-hypertension in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Anti-hypertension in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Anti-hypertension in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Anti-hypertension in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Anti-hypertension in Japan (2016-2028)

SELECT A FORMAT
Added to Cart

Electronic (PDF)
$3250
This license allows only one user to access the PDF.

Electronic (PDF)
$6500
This license allows all the users of an enterprise residing in one location to access the PDF

Electronic (PDF)
$9750
This license allows all the employees of an enterprise to access the PDF.
Add to Cart
Buy Now (10% Discount)
OUR CUSTOMER
SIS Group of Schools

RELATED REPORTS

Global Cardiac Monitoring Products Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Cardiac Monitoring Products Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-10A290
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global and United States Radiation Oncology Market Size Status and Forecast 2021 2027
Global and United States Radiation Oncology Market Size, Status and Forecast 2021-2027

120 Pages
Type: Report
Code: QYRE-Auto-18B3286
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global and China Glucose Meters Market Insights Forecast to 2027
Global and China Glucose Meters Market Insights, Forecast to 2027

120 Pages
Type: Report
Code: QYRE-Auto-13W3412
Mon Sep 27 00:00:00 UTC 2021

Add to Cart

Global Coronary Atherectomy Devices Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027
Global Coronary Atherectomy Devices Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2021-2027

In 2020 the global Coronary Atherectomy Devices market size was US 240 million and it is expected to reach US 375.6 million by the end of 2027 with a CAGR of 6.6 during 20212027.Global Coronary Atherectomy Devices Market Size Manufacturers Supply Chain Sales Channel and Clients 20212027.

120 Pages
Type: Report
Code: QYRE-Auto-12P242
Mon Sep 27 00:00:00 UTC 2021

Add to Cart